Medelis

Executive Summary

Medelis is a Belgium-based, full-service Contract Research Organization (CRO) exclusively focused on oncology drug development. Founded in 2008, the company provides strategic consulting and operational execution for biotech and pharmaceutical sponsors, with a particular emphasis on early-phase and complex immunotherapy trials. By positioning itself as a nimble, expert alternative to large CROs, Medelis leverages deep therapeutic expertise and a collaborative partnership model to differentiate itself in the competitive CRO market. Although the company remains private with no disclosed financials, its long-standing presence in the industry and specialization in a high-growth therapeutic area suggest a stable business trajectory. As oncology drug development continues to advance, Medelis is well-placed to benefit from increasing demand for specialized CRO services, particularly in early-stage and immuno-oncology trials.

Upcoming Catalysts (preview)

• TBDMajor contract win with a biotech or pharma sponsor for an early-phase oncology trial60% success
• TBDExpansion of service offerings into adjacent oncology areas (e.g., CAR-T, bispecifics)50% success
• TBDStrategic partnership or acquisition to enhance capabilities or geographic reach30% success